Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry - Summary - MDSpire

Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry

  • By

  • Marisa Iborra

  • Berta Caballol

  • Alejandro Garrido

  • José María Huguet

  • Francisco Mesonero

  • Ángel Ponferrada

  • Lara Arias García

  • Marta Maia Boscá Watts

  • Samuel J Fernández Prada

  • Eduard Brunet Mas

  • Ana Gutiérrez Casbas

  • Elena Cerrillo

  • Ingrid Ordás

  • Lucía Ruiz

  • Irene García de la Filia

  • Jaime Escobar Ortiz

  • Beatriz Sicilia

  • Elena Ricart

  • Eugeni Domènech

  • Pilar Nos

  • August 22, 2024

  • 0 min

Share

Objective:

To evaluate long-term outcomes after switching from intravenous infliximab (IV-IFX) to subcutaneous biosimilar infliximab (SC-IFX), including drug concentration thresholds for maintaining remission and other predictors for loss of response.

Key Findings:
  • SC-IFX levels significantly increased after switching from IV-IFX.
  • Clinical parameters, CRP, and fecal calprotectin remained unchanged during follow-up.
  • Optimal SC-IFX cutoff concentration for remission was 12-13 μg/mL.
  • Drug persistence was 92% at Week 52 with a good safety profile.
Interpretation:

Switching from IV-IFX to SC-IFX safely maintains long-term remission in IBD patients, with specific trough levels associated with clinical and biochemical remission, suggesting a need for monitoring these levels in practice.

Limitations:
  • Observational study design may limit causal inferences, potentially affecting the reliability of the findings.
  • Single-center data may not be generalizable to all populations, limiting the applicability of the results.
Conclusion:

The study supports the efficacy and safety of SC-IFX in maintaining remission in IBD patients, with identified trough levels that may guide clinical practice.

Original Source(s)

Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry

  • by Marisa Iborra, Berta Caballol, Alejandro Garrido, José María Huguet, Francisco Mesonero, Ángel Ponferrada, Lara Arias García, Marta Maia Boscá Watts, Samuel J Fernández Prada, Eduard Brunet Mas, Ana Gutiérrez Casbas, Elena Cerrillo, Ingrid Ordás, Lucía Ruiz, Irene García de la Filia, Jaime Escobar Ortiz, Beatriz Sicilia, Elena Ricart, Eugeni Domènech, Pilar Nos

  • August 22, 2024

Related Content

Editorial: Volume II of the Community Series on Gut Microbiota and Immune Interactions in Intestinal Disorders

Association Between Delivery Method and Offspring's Risk of Inflammatory Bowel Disease: A Comprehensive Systematic Review and Meta-Analysis

Strategies for Organ Regeneration Using Cell Therapy